We would love to hear your thoughts about our site and services, please take our survey here.
Https://www.lse.co.uk/rns/VAL/proposed-appointment-of-non-executive-director-f12nhzo9af1tobc.html
Want to share insights, ask questions and chat elsewhere? Join the Val Telegram group via: https://twitter.com/AIMhigher100/status/1714204380331688366
Updates on 301 and lab revenue next week for sure. There was a quarterly update last year on 6 Dec. We're due one
And the BOD can only sit on the results of the last assays for 301 for so long without breaching rules.
The 45 period for merger of EUDA and TheoremRx was an exclusivity period, not a deadline. Having said that, Nasdaq rules require that EUDA holders be updated soon. Obviously we need an update as soon as things are concluded. Personally, I'm expecting news on 201 early next week, perhaps as part of the quarterly update. The make or break nature of this 201 licence is what makes Val such an interesting investment right now!
Look forward press releases : https://www.nasdaq.com/market-activity/stocks/lax/press-releases
Solid interview.
Now, in the 16 working days left in 2023 we just need:
Positive outcome to 201, including cash.
Positive update on lab contracts, including cash
301 update (even if it's to say that it's a dead duck)
At least two more new evaluations
Have I missed anything? If we get these, and I think we may well, it'll be starting to make up for good news void of the last couple of years.
Agree with TDK about cash position holding VAL back. This is the only reason for the muted response of the sp to the Stingray evaluation and this 401 licence news. Follows that, once the cash situation is in hand, which will hopefully be very soon, there will be a re-rate.
What we know (almost) for sure is that within the next 2-3 weeks, at the latest, Val will be up alot or down alot. Most holders, like me, think odds favours up alot. Otherwise it wouldn't make sense to be invested. Little to say though until there's news on the 201 licence since everything else is relatively inconsequential in the short term.